Program
PfSPZ-LARC2 Vaccine
Its studies are mostly in Malaria, Falciparum, led by Sanaria.
Furthest: phase 2, since Jun 17, 20264 company-led studies, 3 open or runningNext primary completion: Aug 30, 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sanaria | 43 open or running | phase 2since Jun 17, 2026 | Oct 18, 2024 | Aug 30, 2027phase 1 · NCT06862453 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 18, 2024First study: phase 1 study in Malaria, FalciparumFirst studyNCT06652737 · 75 enrolled · Burkina Faso
- Mar 2, 2025Phase 1 study in Malaria, FalciparumNCT06862453 · 42 planned · Germany
- Jun 17, 2026Phase 2 study in Malaria, FalciparumPhase 2 reachedNCT07675785 · 300 planned · Mali
- Jul 16, 2026Phase 1 study in Malaria, FalciparumNCT07730177 · 45 planned · Burkina Faso
Ahead
- Aug 30, 2027Primary completion: phase 1 study in Malaria, FalciparumNCT06862453
- Dec 2027Primary completion: phase 1 study in Malaria, FalciparumNCT07730177
- Jul 15, 2028Primary completion: phase 2 study in Malaria, FalciparumNCT07675785
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“PfSPZ-LARC2 Vaccine”name, by rule
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07730177Malaria, Falciparum · Burkina Faso | 1 | Not yet recruiting | Dec 2027 | 45 |
| NCT07675785Malaria, Falciparum · Mali | 2 | Recruiting | Jul 15, 2028 | 300 |
| NCT06862453Malaria, Falciparum · Germany | 1 | Recruiting | Aug 30, 2027 | 42 |
| NCT06652737Malaria, Falciparum · Burkina Faso | 1 | Completed | Feb 18, 2026 | 75 |
How it is read
Names in the registry
- “PfSPZ-LARC2 Vaccine”, 4 entries
Conditions, from the studies’ own filings
- Malaria, Falciparum, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.